Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.53 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979446 | 0.84 | MAPT (0.73) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL4162219 | 0.80 | MAPT (0.69) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL7397667 | 0.78 | GSK3B (0.69) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL6350624 | 0.77 | KDM4E (0.69) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL29855719 | 0.77 | MAPT (0.69) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL1655185 | 0.77 | PRKD1 (0.84) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL6241086 | 0.77 | KDM4E (1.00) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL6236970 | 0.77 | KDM4E (0.69) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL6237719 | 0.77 | KDM4E (0.69) | MAPTLMNAHTTTDP1NCOA1 | |
| SCHEMBL5263677 | 0.77 | MAPT (0.69) | MAPTLMNAHTTTDP1NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | PHARMACIA CORPORATION (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005009370-A2 | BETA-CARBOLINE COMPOUNDS AND ANALOGUES THEREOF AND THEIR USE AS MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004113336-A1 | CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | PINTOR JESUS J (ES) | 2004-10-07 | — | — | US | disclosed |
| US-6730707-B2 | SUCH AS 5-(METHOXYCARBONYLAMINO)-N-ACETYLTRYPTAMINE; TREATING OCULAR HYPERTENSION, VARIOUS FORMS OF GLAUCOMA | INSPIRE PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137220-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAPKAPK2, MAP4K2, MAP3K2 | MAPT 1892/4885LMNA 3942/4885HTT 3086/4885 |
| US-20040198803-A1 | Such as 5-(methoxycarbonylamino)-N - acetyltryptamine; therapy for ocular hypertension; vision defects | MTNR1A, MTNR1B, MC5R | MAPT 1007/4885LMNA 1813/4885HTT 429/4885 |
| US-20020037887-A1 | Method for reducing intraocular pressure using indole derivatives | MTNR1A, MTNR1B, MC5R | MAPT 987/4885LMNA 2067/4885HTT 370/4885 |
| US-20050143371-A1 | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | MAP4K2, MAPKAPK2, MAP3K2 | MAPT 2076/4885LMNA 2064/4885HTT 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.